We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 4.09% | 114.50 | 113.00 | 116.00 | 114.50 | 110.00 | 110.00 | 660,062 | 13:35:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Testing Laboratories | 19.5M | 724k | 0.0086 | 133.14 | 96.72M |
TIDMDXRX
Diaceutics PLC
30 November 2023
Diaceutics to attend Stifel and LSE 'Best of British' Conference in NYC
Belfast and London, 30 November 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical and biotech industry, announces that management will attend the Stifel 5(th) Annual 'Best of British' Discovery Conference at the London Stock Exchange's NYC offices on 13 December 2023.
Enquiries:
Hot Features
Premium
Diaceutics PLC
Peter Keeling, Chief Executive Officer Tel: +44 (0)28 9040
6500
Ryan Keeling, Chief Executive Officer investorrelations@diaceutics.com
Designate
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almastrategic.com
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network (R)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAEAEFPAELDFAA
(END) Dow Jones Newswires
November 30, 2023 02:00 ET (07:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
